ARVINAS, INC.
ARVINAS, INC. (ARVN): 10 pipeline candidates · ~26 mo cash runway · 7 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
25.7 months
D/E 0.67 · 0% dilution
Lead: Phase 3
10 candidates
N/A
1 buy · 20 sells (180d)
A transparent, data-derived signal for ARVINAS, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$489.1M
Cash
$87.3M
Quarterly Burn
$69.2M
Runway
25.7 mo
Revenue
$15.6M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (10 candidates)
| Drug | Phase |
|---|---|
| ARV-027 | Phase 2 |
| ARV-102 | Phase 2 |
| ARV-110 | Phase 1/Phase 2 |
| ARV-393 | Phase 1 |
| ARV-471 | Phase 2 |
| ARV-806 | Phase 1/Phase 2 |
| Bavdegalutamide | Phase 1 |
| KRAS G12D Program | Preclinical |
| Luxdegalutamide | Phase 1 |
| vepdegestrant | Phase 3 |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
204
Total value held
$521.2M
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 6,797,584 | $72.1M |
| vanguard capital management llc | 5,378,724 | $57.0M |
| vanguard portfolio management llc | 3,889,628 | $41.2M |
| d. e. shaw & co., inc. | 3,638,567 | $38.6M |
| armistice capital, llc | 1,978,000 | $21.0M |
| two sigma investments, lp | 1,832,114 | $19.4M |
| state street corp | 1,828,472 | $19.4M |
| geode capital management, llc | 1,557,107 | $16.5M |
| jacobs levy equity management, inc | 1,441,521 | $15.3M |
| citadel advisors llc | 1,227,488 | $13.0M |
Showing top 10 of 204 institutional holders of ARVINAS, INC.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in ARVINAS, INC.'s pipeline?
ARVINAS, INC. (ARVN) has 10 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is ARVINAS, INC.'s lead drug candidate?
ARVINAS, INC.'s most advanced tracked candidate is ARV-027 (Phase 2) for Polyglutamine-expanded androgen receptor in skeletal muscle.
What is ARVINAS, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, ARVINAS, INC. has approximately 25.7 months of cash runway.
What is ARVINAS, INC.'s market capitalization?
ARVINAS, INC.'s market capitalization is approximately $489.1M.
Who is the CEO of ARVINAS, INC.?
Dr. Randy Teel Ph.D. is the chief executive officer of ARVINAS, INC. (ARVN).
Get the full picture on ARVINAS, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.